Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In earlier randomized trials, an improvement in OS was seen in two studies,132,133 but other studies failed to show such an improvement.134,135”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [132]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Research works printed but not linked: 7
- Barlogie B, 1991, Bone Marrow Transplant, 7, 71
- Fermand J-P, 1999, Blood, 94, 396a
- Blade J, 2001, Blood, 98, 815a
- Palumbo A, 2001, Blood, 98, 849a
- Fermand J-P, 2001, Blood, 98, 815a
- Richardson P, 2002, Blood, 100, 104a
- Sirohi B, 2002, Bone Marrow Transplant, 29, S12
Cited by
Items 901–987 of 987
Plasma Cell Dyscrasias: Hematopoietic Cell Transplants
Abutalib, S. A. (2017) · Cambridge University Press eBooks · doi:10.1017/9781316335727.047
VII. Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Nakaseko, C. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.1246
Enhancement of death receptor-mediated apoptosis in multiple myeloma cells
Arhoma, A. A. (2017) · Sheffield Hallam University · doi:10.7190/shu-thesis-00026 · Cited by 1
“XXV Abbreviations 2D Two-dimensional 3D Three-dimensional AIF Apoptosis-inducing factor ALDH Aldehyde Dehydrogenase AML Acute Myeloid Leukaemia Apaf-1 Apoptotic Protease Activating Factor-1 AR Antigen Retrieval ASCT Autologous Stem Cell Transplantation ATLL Adult T-cell Leukaemia/Lymphoma ATP Adenosine-5'-Triphosphate…”
BackgroundInfluentialPitcher, D. S. (2016) · Spiral (Imperial College London) · doi:10.25560/50697
Role of Hematopoietic Cell Transplantation for Myeloma
Landau, H. J., & Giralt, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_29
Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Chakraborty, R., & Gertz, M. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_28
Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of New Drugs
Pirogova, O. V., Darskaya, E. I., Porunova, V. V., Kudyasheva, O. V., Smirnova, A. G., Moiseev, I., Бабенко, Е. В., & Afanas’ev, B. V. (2018) · Clinical oncohematology · doi:10.21320/2500-2139-2018-11-2-187-191
“Тем не менее средняя продолжительность ответа после аутоТГСК составляет менее 3 лет и у большинства пациентов наблюдаются рецидивы/прогрессирование заболевания [6].”
Post-Transplantation Management Strategies
Khan, M., Elmaaz, A., & Gul, Z. (2018) · InTech eBooks · doi:10.5772/65239
Stem cell transplantation Hermann Einsele
Einsele, H. (2013) · doi:10.2217/ebo.13.293
Therapie jüngerer Patienten mit multiplem Myelom
Strifler, S., & Einsele, H. (2018) · Der Onkologe · doi:10.1007/s00761-018-0393-0
“2 aufeinanderfolgende HDT mit autoPBSCT) konnten weder einzelne prospektive Studien [1, 6] noch 2 große Metaanalysen [16, 24] die Frage abschließend beantworten.”
BackgroundChen, A., Hoppe, R. T., & Coutre, S. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5897-7.00065-2
MULTIPLE MYELOMA- ANALYSIS OF DIAGNOSTIC CRITERIA AND PROGNOSTIC FACTORS
Prema, K. R., K, P. K., & Jose, M. (2018) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2018/700
Multiple Myeloma and Other Plasma Cell Neoplasms
Ng, A. K., Anderson, K. C., & Mahindra, A. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00076-6
Miguel, J. F. S., & Bladé, J. (2010) · Wiley eBooks · doi:10.1002/9781444323160.ch31 · Cited by 1
Stem cell transplant and the potential role of CAR-T cells in multiple myeloma
Sabbagh, N., & Zander, A. R. (2018) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2018-7-4-8-15
Cioch, M. (2019) · Acta Haematologica Polonica · doi:10.2478/ahp-2019-0021 · Cited by 1
Evaluation of mobilization efficacy with an extended interval following plerixafor administration
Stump, S. E., Trepte, M., Shaw, J. R., Grgic, T., Ptachcinski, J. R., Sharf, A., Riches, M., Shea, T. C., Park, Y. A., & Alexander, M. D. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219900909
Hämatologische und onkologische Erkrankungen
Schrezenmeier, H., & Hiller, E. (2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50012-1
van Rhee, F., & Nair, B. P. (2009) · Elsevier eBooks · doi:10.1016/b978-0-443-10147-2.50012-6 · Cited by 1
Jung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O., Pfeifer, R., Schellinger, P. D., Weiss, N., & Wendtner, C. ‐. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50009-7
Transplant Pharmacology and Conditioning Therapy
Bajel, A. R. (2020) · Organ and tissue transplantation · doi:10.1007/978-3-319-64938-2_22-1
M Sc. Nursing, C., Singh, T., Pakhide, M. V., & Verma, M. M. (2021) · International Journal of Medical Research and Review · doi:10.17511/ijmrr.2021.i02.01
Mamaeva, E. A., Менделеева, Л. П., Solovev, M. V., Фирсова, М. В., Крайзман, А. А., Арутюнян, Н. К., Abakumova, A. V., Startsev, A. A., Makunina, E. A., Kondratieva, Y. A., et al. (2021) · Гематология и трансфузиология · doi:10.35754/0234-5730-2021-66-4-512-525
Multiple Myeloma Surveillance Counterpoint: Australia
Khoo, L., & Joshua, D. (2012) · Humana Press eBooks · doi:10.1007/978-1-60327-969-7_100
Investigation of the intrinsic mechanism of drug resistance in multiple myeloma
Ooi, M. G. M. (2011) · Dublin City University Open Access Institutional Repository (Dublin City University)
Leer.es, E. V. (2011) · Aula de innovación educativa
Stem Cell Transplantation in Multiple
Koreth, J., & Anderson, K. C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-438-4_8
“The published trial compared single versus double HDT, each preceded by Mel140+TBI conditioning, and reported a PFS and OS benefit in the double transplant arm at seven years [ 42 ].”
BackgroundMethodCurrent Awareness in Hematological Oncology
(2004) · Hematological Oncology · doi:10.1002/hon.719
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt011
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Galimberti, S., Boni, R., & Erba, P. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-26236-9_48
Bianchi, G., & Anderson, K. C. (2018) · Wiley eBooks · doi:10.1002/9781118592168.ch33
Beelen, D. W., Scheulen, M. E., Flaßhove, M., Bojko, P., Moritz, T., & Beelen, D. W. (2007) · Springer eBooks · doi:10.1007/978-3-540-28978-4_13
Hematopoietic Cell Transplantation for Multiple Myeloma
Krishnan, A. Y., & Giralt, S. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch55
Nowrousian, M. R., Schütt, P., & Müller, S. (2007) · Springer eBooks · doi:10.1007/978-3-540-28978-4_23
(2006) · Cancer Investigation · doi:10.1080/07357900600560838
Ludwig, H., & Schmoll, H. (2006) · Springer eBooks · doi:10.1007/3-540-31303-6_191
Paraproteinämien / Multiples Myelom
Holzer, S., & Drach, J. W. (2008) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-008-0040-6
Mieloma múltiplo não secretor em cão Shih Tzu: relato de caso
Carrera, A. L. C., Moreno, I. F., Luz, M. B., Requena, R., & Russo, C. (2022) · Medicina Veterinária (UFRPE) · doi:10.26605/medvet-v16n1-3509 · Cited by 75
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_48-2
Ludwig, H. (2006) · Springer eBooks · doi:10.1007/3-540-26504-x_70
Schlossman, R. L. (2006) · Springer eBooks · doi:10.1007/0-387-31056-8_69
Masche, U. (2005) · pharma-kritik · doi:10.37667/pk.2004.112
Baz, R., & Bolwell, B. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6643-9.00093-x
Moreau, P. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0021-9_46 · Cited by 1
Tantravahi, S. K., & Kovacsovics, T. J. (2015) · Springer eBooks · doi:10.1007/978-1-4614-5662-9_9
Selected Organ System Abnormalities
(2007) · Elsevier eBooks · doi:10.1016/b978-0-323-03671-9.50012-5
Erkrankungen des lymphatischen Systems
Sieber, M., Wolf, J., Diehl, V., Reiser, M., Engert, A., & Voliotis, D. (2006) · Springer eBooks · doi:10.1007/3-540-27385-9_30
Multiple Myeloma, a Clinical Case
Сало, М. О., Петриченко, О. М., Балашова, О. И., & Довбня, А. О. (2020) · Евразийский онкологический журнал · doi:10.34883/pi.2020.8.3.016
Mina, R., & Palumbo, A. P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2837-3_12
(2007) · Elsevier eBooks · doi:10.1016/b978-032304195-9.50013-4
Armoiry, X., Aulagner, G., & Henaine, A.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-2-294-76375-5.00026-9
Multiple Myeloma and Plasmacytoma
Chng, W. J., & Lu, J. J. (2008) · Medical radiology · doi:10.1007/978-3-540-77385-6_29
Tan, Y. H., Xu, S., Li, X., & Chen, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010484
RetractedRole of Autologous Stem Cell Transplantation in Multiple Myeloma
Harousseau, J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_6
Self-citationOrlowski, R. Z., & Gabriel, D. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4417-8.50083-8
Biology-Based Classification and Staging of Multiple Myeloma
Chng, W. J., & Bergsagel, P. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_4
Al-Anazi, K. A., Mutahar, E. Y., Abduljalil, O., Kanfer, S., Kaloyannidis, P., Estanislao, A., Apostolidis, I., Almokhtar, N., Darweesh, M., Abdulbaqi, M., et al. (2022) · Journal of Stem Cell Therapy and Transplantation · doi:10.29328/journal.jsctt.1001027
Yee, A. J., Hideshima, T., Raje, N. S., & Anderson, K. C. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122.pub2
An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
Al‐Anazi, K. A., Alshaibani, Z., & Kalogiannidis, P. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109059
Oehlbaum, E., Ring, A., Balakrishna, S., & Müller, A. M. S. (2022) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2022.13.084
Burington, B. E., Barlogie, B., Zhan, F., Crowley, J. J., & Shaughnessy, J. D. (2023) · doi:10.1158/1078-0432.c.6516871
Hematopoietic Cell Transplantation in Multiple Myeloma
Ghanem, S., & Qazilbash, M. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00021-8
Stem Cell Transplant for Plasma Cell Dyscrasias
Sharma, S. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-5802-1_25
Stem cell based informatics development and approaches
Chandra, A., Goyal, N., Singh, N., Goel, V. K., Agarwal, S., & Arya, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13222-3.00026-5
Decreasing or Increasing Role of Autologous Stem Cell Transplantation in Multiple Myeloma?
Salamoon, M. (2020) · Clinical Research in Hematology · doi:10.33309/2639-8354.030103
“[40] The former results were supported by an Italian study conducted by Cavo et al . demonstrated better response and PFS rates; however, OS was similar in both arms (median, 71 vs. 65 months; P = 0.9).”
ResultInfluentialAlegre, A. M., Gironella, M., Escalante, F., Bergua, J., Martínez‐Chamorro, C., López, A., González, E., Bárez, A., Somolinos, N., Persona, E. P., et al. (2024) · HemaSphere · doi:10.1002/hem3.81 · Cited by 1
Baljević, M., Biltibo, E. A., Dholaria, B., & Sengsayadeth, S. M. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.08.003
Revision of criteria for the diagnosis and evaluation of response to therapy in multiple myeloma
Maisnar, V., & Hájek, R. (2008) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2008.018
Costello, C. L., & Fonseca, R. (2022) · doi:10.1182/ashsap8.chapter25
Hematopoietic cell transplantation and cellular therapy
Khan, I., Shah, N. N., & Ulrickson, M. L. (2022) · doi:10.1182/ashsap8.chapter14
Renzo, N. D., Resta, E., Dargenio, M., Sgherza, N., Tarantini, F., Reddiconto, G., Renzo, G. D., Federico, V., Fina, M. P., Matera, R., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06627-0
Current Status of BoneMarrow Transplantation for Treatment of Cancer
Ball, E. D., Bashey, A., Carrier, E., Castro, J. E., Holman, P., & Lane, T. A. (2010) · Springer eBooks · doi:10.1007/978-90-481-9704-0_23
“Initial results were presented at the 2002 American Society of Hematology meeting; results were updated with the benefit of additional follow-up at the IX International Myeloma Workshop [9].”
BackgroundMultiples Myelom und verwandte Plasmazellerkrankungen
Sezer, O. (2007) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50037-6
Wang, S.-Y. (2023) · Qucosa (Saxon State and University Library Dresden)
Mieloma múltiple : canvis en el maneig clínic associats a la incorporació de nous fàrmacs
Gassiot-Riu, S., & de Medicina, U. A. D. B. D. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Kumar, M., Jasuja, S. K., Goel, K., Mittal, A., Ramkrishan, R., Mittal, L., Kapuria, S., & Yadav, J. (2023) · DergiPark (Istanbul University)
Ali, N., Ahmed, D., Iftikhar, R., Iftikhar, A., Anwar, N., Bokhari, S. W., Zaidi, U., Ahmad, U., Sarwar, S., Humayun, S., et al. (2026) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.70104
Rôle de la voie IGF-1 dans la sensibilité des plasmocytes tumoraux aux inhibiteurs du protéasome
Tagoug, I. (2010) · theses.fr (ABES) · doi:10.70675/53ca31a0z7f7fz427cz8969z2fb28a03343f
Exploration des récepteurs à dépendance dans les hémopathies malignes
Fahed, D. (2020) · theses.fr (ABES) · doi:10.70675/621dee0ez6dd8z4539z81a4z388f4a3296af
The genetic architecture of plasma cell disorders
Boyle, E. M. (2020) · theses.fr (ABES) · doi:10.70675/404c872dz0ef2z4f8eza81fz592360ed443b · Cited by 1
De-escalation trials in multiple myeloma: past, present and future
Mian, H. S., Costa, L. J., Mohty, M., Garfall, A. L., & Rajkumar, S. V. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01186-3
Conditioning Regimen for Hematopoietic Stem Cell Transplant
Choudhary, D. R., Doval, D., & Patel, N. (2026) · Springer eBooks · doi:10.1007/978-981-92-1167-8_42
Multiple Myeloma Surveillance Counterpoint: Japan
Takenaka, K. (2012) · Humana Press eBooks · doi:10.1007/978-1-60327-969-7_101
Guimarães, P. L. C. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/30e0-te80
Augmentation of Hematopoietic Stem Cell Transplantation with Anti-cancer Vaccines
Ball, E. D., & Holman, P. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-478-0_46
“In MM, even though the introduction of newer targeted therapies is challenging this approach, HDT/ASCT (single or tandem) is widely accepted as initial standard consolidation therapy for younger patients with stage 2 and 3 disease [17, 18].”
Background
Metadata
- Authors
- Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
- Affiliations
- Hôpital Purpan (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Henri Becquerel (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Albert Michallon (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-25
- Volume
- 349
- Issue
- 26
- Pages
- 2495-2502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982499121
- Cited by
- 984
- References
- 16
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.